8-K: Aquestive Therapeutics Faces Anaphylm Delay, Plans Q3 2026 Resubmission

Aquestive Therapeutics received a Complete Response Letter for Anaphylm, delaying its approval, but plans a Q3 2026 resubmission backed by a strong cash position.

Summary

• Aquestive Therapeutics, Inc. (NASDAQ: AQST) received a Complete Response Letter (CRL) from the FDA for its Anaphylm (dibutepinephrine) sublingual film on January 30, 2026.
• The company expects to resubmit the New Drug Application (NDA) for Anaphylm in Q3 2026, following a Type A meeting with the FDA in Q1 2026 and additional studies.
• Anaphylm is positioned as the first and only non-device based, orally delivered epinephrine product candidate for severe allergies and anaphylaxis, with a potential annual revenue opportunity exceeding $500 million.
• The U.S. epinephrine market is projected to grow from approximately $850 million in 2025 to $2 billion by 2031.
• Aquestive finished 2025 with $121.2 million in cash and cash equivalents, stating it is well-capitalized to address the Anaphylm CRL and expects to finish 2026 with significant cash.
• The company's pipeline also includes Libervant (diazepam) buccal film for acute repetitive seizures (potential >$1 billion annual revenue) and AQST-108 (epinephrine) topical gel for alopecia areata (potential >$100 million annual revenue).
• AQST-108 is currently in Phase 1 clinical studies, with an IND opened in Q4 2025 and further studies planned for Q1 and 2H 2026.
• A Q3 2025 capital raise is noted as having validated investor belief in Anaphylm's commercial promise.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development due to the Anaphylm CRL, which introduces uncertainty and delays. However, the company's strong cash position and clear plan for resubmission, coupled with a diversified pipeline, mitigate a more severe negative sentiment.

Positives

• Aquestive Therapeutics ended 2025 with a strong cash position of $121.2 million, providing capital to address the Anaphylm CRL and fund operations through 2026.
• The company has a diversified pipeline with two other proprietary growth drivers, Libervant and AQST-108, targeting significant market opportunities.
• Anaphylm addresses a clear unmet need for a needle-free, orally delivered epinephrine, with 96% of survey respondents preferring the film over a nasal spray.
• The U.S. epinephrine market is expanding, projected to reach $2 billion by 2031, offering substantial commercial opportunity for Anaphylm if approved.
• The AdrenaVerse technology platform enables the pursuit of various allergy and dermatological indications, as demonstrated by AQST-108.

Negatives

• The receipt of a Complete Response Letter (CRL) for Anaphylm on January 30, 2026, delays its potential FDA approval and commercial launch.
• The resubmission of the Anaphylm NDA is not expected until Q3 2026, pushing back the potential approval timeline.
• Expedited review for the Anaphylm NDA resubmission cannot be guaranteed, potentially leading to a standard six-month review period.
• The company faces risks associated with addressing the FDA's concerns outlined in the CRL, which may require additional clinical studies or information.

Risks

• Delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm and AQST-108.
• Delays in advancement of the regulatory approval process through the FDA for Anaphylm, Libervant, and AQST-108, or failure to receive FDA approval at all.
• Risk of FDA inspections of manufacturing and clinical study sites for any product candidates.
• Risk of government shutdowns or actions affecting the FDA's ability to act on product approvals.
• Inability to generate sufficient clinical and other human factor data, including pharmacokinetic and pharmacodynamic (PK/PD) comparability data for Anaphylm.
• Challenges in addressing the FDA's comments and identified deficiencies in the Anaphylm NDA, including concerns raised in the CRL, and potential requests for further information or additional clinical studies.
• Risk that the FDA may consider issues raised in the citizen petition submitted regarding Anaphylm on October 1, 2025.
• Risks associated with the success of competing products, including generics.
• Risks and uncertainties inherent in commercializing a new product, including technology, financial, market, implementation risks, and regulatory limitations.
• Risk of developing a sales and marketing capability for commercialization of product candidates.
• Risk of insufficient capital and cash resources to satisfy short-term and longer-term liquidity and cash requirements, including principal payments on 13.5% Senior Secured Notes in 2026.
• Impact of obligations under Purchase Agreement and Royalty Rights Agreement on funding operations and ability to refinance debt.
• Risk that manufacturing capabilities will be insufficient to support demand for product candidates.
• Risk of eroding market share for Suboxone, which accounts for a substantial part of current operating revenue.
• Risk of default of debt instruments.
• Risks related to outsourcing certain sales, marketing, and other operational functions to third parties.
• Risk of the rate and degree of market acceptance of product candidates.
• Risks associated with intellectual property rights and infringement claims, including timely issuance of patents and their sufficiency for long-term commercial success.
• Risk of unexpected patent developments.
• Risk of legislation and regulatory actions and changes in laws or regulations affecting the business, including product pricing, reimbursement, or access.
• Risk of loss of significant customers.
• Risks related to claims and legal proceedings, including patent infringement, securities, business torts, investigative, product safety or efficacy, and antitrust litigation matters.
• Risk of product recalls and withdrawals.
• Risks related to disruptions in information technology networks and systems, including cybersecurity attacks.
• Risks related to adverse developments affecting the financial services industry, inflation, changing interest rates, and pandemic diseases.
• Risks and uncertainties related to general economic, political, business, industry, regulatory, financial, and market conditions.

Future Outlook

Aquestive Therapeutics plans to resubmit the New Drug Application for Anaphylm in Q3 2026, following a Type A meeting with the FDA and completion of a Human Factors Validation Study and Clinical PK Study. The company anticipates a potential U.S. commercial launch of one of its product candidates in 2027, if approved. For AQST-108, further clinical studies, including a Maximum Tolerated Dose (MTD) finding study and toxicology studies, are planned for 2026. The company expects to finish 2026 with significant cash, supporting its development and commercialization strategies.

Management Comments

• We are well-capitalized to address the Anaphylm Complete Response Letter and expecting to finish 2026 with significant cash.
• The Q3 2025 capital raise validated the belief in the commercial promise of Anaphylm.

Industry Context

StockSavvy.ai notes that the anaphylaxis market is ripe for innovation, with current epinephrine auto-injectors (EAIs) facing significant patient adherence issues due to bulkiness, fear of needles, and administration challenges. Anaphylm's needle-free, orally delivered sublingual film aims to address these long-standing barriers, potentially expanding the overall market beyond the projected $2 billion by 2031. For alopecia areata, AQST-108's topical gel approach could offer a differentiated treatment option, potentially as an alternative or adjunct to existing Janus Kinase (JAK) inhibitors, which do not work for all severe patients.

Comparison to Industry Standards

• Anaphylm is positioned as the first and only non-device based, orally delivered epinephrine product candidate, differentiating it from existing epinephrine auto-injectors (EAIs) like EpiPen and Auvi-Q, and nasal sprays such as Neffy (though no head-to-head studies have been conducted with Anaphylm and Neffy).
• Anaphylm's observed median T-max of 12 minutes and therapeutic blood concentrations in as little as 5 minutes aim to provide rapid relief, comparable to the critical speed required for anaphylaxis treatment.
• AQST-108 for alopecia areata is being developed as a potential alternative or improvement to current treatments, specifically mentioning Janus Kinase (JAK) inhibitors, which may not be effective for two-thirds of severe patients.

Legal Proceedings

• Risk of claims and legal proceedings against the company, including patent infringement, securities, business torts, investigative, product safety or efficacy, and antitrust litigation matters.

Stakeholder Impact

• Shareholders may experience short-term negative impact due to the Anaphylm CRL and associated delays, but the company's strong cash position and pipeline offer long-term potential.
• Patients at risk for anaphylaxis will face a delay in accessing Anaphylm, a potentially needle-free and convenient treatment option.
• Employees will continue development work and commercialization planning, with the company's financial stability supporting ongoing operations.
• Creditors, particularly holders of the 13.5% Senior Secured Notes, will note the company's commitment to commence principal payments in 2026 and its strong cash position.

Next Steps

• Hold a Type A Meeting with the FDA in Q1 2026 regarding Anaphylm.
• Conduct a Human Factors Validation Study for Anaphylm in Q2 2026.
• Resubmit the New Drug Application (NDA) for Anaphylm in Q3 2026, requesting expedited review.
• Conduct a Clinical PK Study for Anaphylm in Q4 2026.
• Initiate Ex-US filings (Canada, Europe) for Anaphylm in Q1 2027.
• Continue clinical development for AQST-108, including MTD/Biomarker Trial and Phase 1 One Week Safety & PK trial in Q1 2026.
• Conduct a Maximum Tolerated Dose (MTD) Finding Study and 90-day Sub Chronic Toxicology Study for AQST-108 in 2H 2026.
• Build commercial infrastructure and engage with payers, prescribers, and advocacy groups in 2026 for Anaphylm launch preparation.

Key Dates

Recommendation

The Complete Response Letter for Anaphylm is a significant setback, introducing regulatory uncertainty and delaying a key product launch. However, Aquestive's strong cash position ($121.2M at year-end 2025), clear plan for resubmission, and diversified pipeline with other high-potential assets (Libervant, AQST-108) provide a floor for the stock. A seasoned investor would likely 'hold' to monitor the progress of the Anaphylm resubmission and the development of other pipeline candidates, as the long-term thesis for the company's innovative drug delivery platforms remains intact despite this near-term hurdle.

Keywords

Aquestive Therapeutics, Anaphylm, dibutepinephrine, sublingual film, anaphylaxis, epinephrine, FDA CRL, NDA resubmission, Libervant, diazepam buccal film, AQST-108, alopecia areata, PharmFilm, AdrenaVerse, biopharmaceutical, drug delivery, pharmaceuticals